Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
41 hedge funds and large institutions have $14.1M invested in Viracta Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 11 closing their positions.
200% more call options, than puts
Call options by funds: $9K | Put options by funds: $3K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 48 → 41 (-7)
28% less capital invested
Capital invested by funds: $19.4M → $14.1M (-$5.37M)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$103K |
| 2 |
B
Bailard
Foster City,
California
|
+$39.8K |
| 3 |
HF
HRT Financial
New York
|
+$24.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24K |
| 5 |
BlackRock
New York
|
+$17.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.36M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$477K |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$255K |
| 4 |
JRP
Jasper Ridge Partners
Menlo Park,
California
|
-$148K |
| 5 |
Millennium Management
New York
|
-$130K |
VIRX Hedge Fund Activity: Q2 2023 in Review
41 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2023, worth a combined $14.1M — down 28% from $19.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VIRX and 4 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 7 added.
The largest buyer was Acadian Asset Management, adding an estimated $103K. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $2.36M sold.
- 41 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2023, down from 48 in Q1 2023.
- Funds reported $14.1M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2023, down 28% quarter-over-quarter.
- 4 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2023 and 11 closed out, a net change of -7 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2023 was Acadian Asset Management, an estimated $103K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2023 was Rubric Capital Management (New York), an estimated $2.36M sold.
Based on aggregated 13F filings for Q2 2023.